Approval · Notice of Compliance 21203 · 2018
EDURANT: Notice of Compliance 21203
Issued August 13, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21203
- Date
- August 13, 2018
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety updates to edurant pm with regards to pregnancy and post-partum
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EDURANT | Not yet assigned | — |
Medicinal ingredients
- RILPIVIRINE HYDROCHLORIDE 25 MG per TAB